PsychoGenics Announces Drug Discovery and Development Agreement with Eli Lilly and Company; Companies Will Work Together to Identify New Treatments for Neuropsychiatric Disorders

Dec 19, 2006 - PsychoGenics Inc. today announced that it has entered into a drug discovery and development agreement with Eli Lilly and Company (NYSE: LLY). Per the agreement, Lilly will provide drug candidates that PsychoGenics will evaluate, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Read More.

PsychoGenics Appoints Rusiko Bourtchouladze, Ph.D. as Vice President, Cognition and Discovery Research

October 4, 2006 – PsychoGenics Inc. announced the appointment of Rusiko Bourtchouladze, Ph.D., as Vice President, Cognition and Discovery Research. This appointment reflects the company’s expansion and commitment to cognition and drug discovery. Read More.

PsychoGenics Expands Huntington Disease Research Collaboration with High Q Foundation and CHDI

September 22, 2006- PsychoGenics Inc. Tarrytown, New York has expanded its research collaboration with the High Q Foundation and CHDI Inc. to phenotype transgenic mouse models of Huntington Disease (HD) and evaluate potential therapeutics in those models. Read More.

PsychoGenics and Sosei Partner to Identify New CNS Therapies

April 10, 2006 - PsychoGenics Inc., Tarrytown, NY and Sosei Co. Ltd., Japan, have entered into a drug discovery collaboration combining Sosei’s Drug Reprofiling Platform and PsychoGenics’ proprietary Drug Discovery Systems. This collaboration aims to rapidly discover and bring to market new CNS therapies. Read More.

PsychoGenics and SMA Foundation Extend Research Agreement

February 24, 2006 – PsychoGenics Inc. Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models. As part of this collaborative agreement PsychoGenics has established self-sustaining transgenic SMA colonies and characterized the progression of behavioral and motor deficits in these mice over time. A rapid throughput battery of discriminatory tests has been developed to evaluate candidate drugs and therapies in these models to treat spinal muscular atrophy.Read More.